The South Florida Business Journal reported on the boom in compounded GLP-1s and Scott explained...
Reuters, like many other media outlets, covered Novo Nordisk’s request that the FDA add semaglutide to the Demonstrably Difficult to Compound list. (Silly, we know.)
It quoted APC pointing out that there’s a big difference between creating the semaglutide molecule (tough) and compounding with it (easy).
The South Florida Business Journal reported on the boom in compounded GLP-1s and Scott explained...
Getting away from GLP-1s, Pharmaceutical Executive features CEO Scott Brunner and Chief Advocacy...
Wired wrote about “The Crackdown on Compounded GLP-1 Meds,” where it made clear that it doesn’t...